Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series

Area of Science:

• Oncology
• Medical Research

Background:

• Extracranial, extragonadal germ cell tumors (EGCTs) represent a rare subset of germ cell tumors.
• Understanding treatment patterns and outcomes is crucial for improving patient care.

Purpose of the Study:

• To describe the treatment patterns and outcomes for patients diagnosed with EGCTs in Australia.
• To analyze the incidence and survival rates associated with different EGCT primary sites and subtypes.

Main Methods:

• Retrospective analysis of male patients with EGCTs registered in the Australian GCT clinical registry (iTestis) since 2018.
• Data collected included demographics, clinicopathologic features, treatment details, and outcomes.
• Descriptive statistics and Kaplan-Meier estimates for overall survival (OS) were used for analysis.

Main Results:

• Out of 1256 patients, 33 (3%) had EGCTs, primarily mediastinal (55%) and retroperitoneal (42%).
• Most patients received upfront chemotherapy (82%), commonly bleomycin/etoposide/cisplatin (BEP).
• No deaths were observed in patients with retroperitoneal primary tumors or seminomas; however, primary mediastinal non-seminoma showed poorer outcomes with a 24-month OS of 71%.

Conclusions:

• The incidence of EGCTs in Australia aligns with international data.
• Treatment strategies for EGCTs in Australia mirror global practices.
• Primary mediastinal non-seminoma is associated with the poorest outcomes, while primary retroperitoneal and mediastinal seminomas demonstrate excellent outcomes.